Volker Heinemann

Research interests

Publications

• Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00727-4

• Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.00590

• Advances in cancer immunotherapy 2019 – latest trends

  Journal of Experimental & Clinical Cancer Research · 2019 · 10.1186/s13046-019-1266-0

• Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(18)32557-1

• First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30457-6

• Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx175

• First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30457-6

• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw235

• Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer

  JAMA Oncology · 2016 · https://doi.org/10.1001/jamaoncol.2016.3797

• SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.66.1181

• Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30500-9

• The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials

  European Journal of Cancer · 2016 · 10.1016/j.ejca.2016.10.007

• FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30269-8

• Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

  Annals of Oncology · 2016 · 10.1093/annonc/mdw261

• Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.59.4812

• nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

  JNCI Journal of the National Cancer Institute · 2015 · 10.1093/jnci/dju413

• FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70330-4

• Addressing the challenges of pancreatic cancer: Future directions for improving outcomes

  Pancreatology · 2014 · https://doi.org/10.1016/j.pan.2014.10.001

• Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70212-8

• Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report

  Annals of Oncology · 2009 · 10.1093/annonc/mdp332

• Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

  BMC Cancer · 2008 · 10.1186/1471-2407-8-82

• Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

  Journal of Clinical Oncology · 2006 · 10.1200/jco.2005.05.1490

• Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier

  Anti-Cancer Drugs · 2006 · 10.1097/01.cad.0000236313.50833.ee

• Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

  PubMed · 1995

• Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.

  Molecular Pharmacology · 1990 · 10.1016/s0026-895x(25)09518-5

• Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.

  PubMed · 1988

Current projects

No projects listed.